City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
BVX-0922 to target colorectal cancer under investigator-sponsored IND
The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Subscribe To Our Newsletter & Stay Updated
